Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...

OSAKA, Japan & BOSTON, MA, USA I June 23, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and ...

Chen also says that air pollution harms blood vessels, including the tiny ones in the kidneys, which can reduce blood flow ...

Using CRISPR to correct the mutations behind polycystic kidney disease could counter some of the damage the condition causes ...

She is among many patients now asking why, with no apparent change in their blood test results, chronic kidney disease (CKD) is suddenly appearing as a problem on their medical charts. The answer is ...

Another myth is that dialysis is inevitable if you have kidney disease. However, according to Dr Manual, “Not all patients progress to ESRD (End-Stage Renal Disease).

The Oxalosis and Hyperoxaluria Foundation (OHF) has accepted UCSF Health into its OHF Care Center Network recognizing the health system’s dedication to providing high-quality medical care, resources, ...